Endo International PLC (ENDP) Bonds Rise 1.3% During Trading

An issue of Endo International PLC (NASDAQ:ENDP) debt rose 1.3% as a percentage of its face value during trading on Friday. The high-yield issue of debt has a 7.75% coupon and will mature on January 15, 2022. The bonds in the issue are now trading at $100.25 and were trading at $96.50 last week. Price moves in a company’s debt in credit markets often predict parallel moves in its stock price.

ENDP has been the subject of several recent analyst reports. Royal Bank Of Canada set a $15.00 target price on shares of Endo International PLC and gave the company a “hold” rating in a research note on Saturday, April 8th. Canaccord Genuity restated a “hold” rating and issued a $14.00 target price on shares of Endo International PLC in a research note on Tuesday, April 11th. Mizuho restated a “buy” rating and issued a $18.00 target price (up from $17.00) on shares of Endo International PLC in a research note on Thursday, April 13th. Vetr downgraded shares of Endo International PLC from a “strong-buy” rating to a “hold” rating and set a $11.34 target price for the company. in a research note on Thursday, April 27th. Finally, BMO Capital Markets restated a “hold” rating and issued a $15.00 target price on shares of Endo International PLC in a research note on Monday, May 1st. Two analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and six have assigned a buy rating to the stock. Endo International PLC presently has an average rating of “Hold” and an average target price of $17.33.

Shares of Endo International PLC (NASDAQ ENDP) traded up 0.49% on Friday, hitting $12.38. 2,543,418 shares of the company traded hands. The stock’s 50-day moving average price is $11.73 and its 200-day moving average price is $12.05. The company’s market capitalization is $2.76 billion. Endo International PLC has a 12 month low of $9.70 and a 12 month high of $24.93.

Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings results on Tuesday, May 9th. The company reported $1.23 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.10 by $0.13. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.02 billion. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. Endo International PLC’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.08 EPS. On average, equities analysts predict that Endo International PLC will post $3.55 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the company. Amalgamated Bank increased its position in shares of Endo International PLC by 2.0% in the first quarter. Amalgamated Bank now owns 32,357 shares of the company’s stock worth $361,000 after buying an additional 619 shares during the last quarter. Meeder Asset Management Inc. increased its position in shares of Endo International PLC by 1.4% in the second quarter. Meeder Asset Management Inc. now owns 48,699 shares of the company’s stock worth $544,000 after buying an additional 677 shares during the last quarter. Capstone Asset Management Co. increased its position in shares of Endo International PLC by 3.1% in the second quarter. Capstone Asset Management Co. now owns 32,035 shares of the company’s stock worth $358,000 after buying an additional 960 shares during the last quarter. Point View Wealth Management Inc. increased its position in shares of Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock worth $128,000 after buying an additional 1,254 shares during the last quarter. Finally, Oakbrook Investments LLC increased its position in shares of Endo International PLC by 8.2% in the second quarter. Oakbrook Investments LLC now owns 17,100 shares of the company’s stock worth $191,000 after buying an additional 1,300 shares during the last quarter. Institutional investors own 93.17% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://sportsperspectives.com/2017/07/21/endo-international-plc-endp-bonds-rise-1-3-during-trading.html.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply